Streetwise Reports' Article Archives — October 2018 back to current month (23)
A ROTH Capital Partners report outlines its reasons for initiating coverage on this epigenetic therapeutics developer, whose lead candidate is in trials in diabetes, end-stage renal disease and other indications.
With this achievement, the firm expands its potential partnering opportunities.
Three Small-Caps on This Fund Manager's List (10/30/2018)
Steve Palmer, founding partner, President and Chief Investment Officer of AlphaNorth Asset Management, talks with Streetwise Reports about several small-cap companies from three sectors that he has been following.
Technical analyst Clive Maund provides an update on a company whose product is replacing antibiotics for growth promotion in animal feed.
Multiple governments around the world have unleashed mandates on livestock feed regulations that pose an opportunity for a Canada-based biotech company.
Dr. Amit Kumar, CEO of Anixa Biosciences, sits down with Daniel Carlson of Tailwinds Research to discuss the company's trials of CAR-T for solid tumors, as well as its Cchek program to distinguish between benign conditions and malignant cancer.
Catasys…Future's So Bright (10/27/2018)
Daniel Carlson of Tailwinds Research discusses a company that helps health plans solve the hidden, high-cost problem of untreated behavioral health conditions.
A Maxim Group report discussed the potential implications of this new collaboration in the field of personalized medicine and oncology.
Fincom Investment Partners previews Q3 earnings estimates for a company that it believes offers the best value in cannabis/hemp.
This Canadian company makes progress with its commercial uptake efforts.
An H.C. Wainwright & Co. report delivered the latest news regarding one of this immunotherapy firm's platforms, including the receipt of the first-ever U.S. patents for DNA-encoded monoclonal antibody technology.
Canada-based biotech company signs major deal with Chinese partner to advance groundbreaking technology in the skin and tendon rejuvenation space.
This company's findings to date for its topical therapy candidate have encouraging implications for an orphan indication.
This "patient-care solution" is designed to help retailers make product recommendations.
Testing conducted as part of this Canadian company's research and development work on Parkinson's disease therapeutics has identified new potential antibody candidates.
A LifeSci Capital report presented a handful of key points about the firm.
An H.C. Wainwright & Co. report covered the greenlighting of two therapeutics developed by this firm, whose stock, according to the analyst, has more than fivebagger return potential.
Texas Heart Takes to the CoreoGraft (10/10/2018)
Daniel Carlson of Tailwinds Research profiles Hancock Jaffe Laboratories, which is partnering with the Texas Heart Institute to further develop an innovative graft designed for use in coronary bypass surgery.
This Utah-based company rolled out an online campaign that highlights its strategic repositioning.
A new, once-monthly injectable treatment for schizophrenia uses patents of a small-cap, U.S.-based pharmaceutical firm.
An H.C. Wainwright & Co. report reviewed this company's Q4/18 earnings and opportunities for increasing it.
A Ladenburg Thalmann report relayed how this Massachusetts company participated at the Transcatheter Cardiovascular Therapeutics annual meeting through a live transmission—the first ever—of a remote interventional procedure using the CorPath GRX system.
As the worldwide movement to ban antibiotics as a growth promoter in animal feed gains traction, technical analyst Clive Maund has called an "immediate strong buy" on a company that has developed an alternative.
|"From a stock perspective, 2019 was a clear breakout year for DRRX."|